Ceftriaxone for Post-Treatment Lyme Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions

Post-Treatment Lyme Disease Syndrome

Interventions

DRUG

Ceftriaxone treatment

9 infusions spaced out approximately every 5 days

DRUG

Placebo

D5W (placebo)

Trial Locations (1)

RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors

collaborator

Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases

UNKNOWN

lead

Hackensack Meridian Health

OTHER

NCT06785402 - Ceftriaxone for Post-Treatment Lyme Disease | Biotech Hunter | Biotech Hunter